FMS-like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia (AML) Patients with Normal Karyotype; Mutation Status and Clinical and Laboratory Characteristics

Rezaei, Narges; Arandi, Nargess; Valibeigi, Behnaz; Haghpanah, Sezaneh; Khansalar, Mehdi; Ramzi, Mani

doi:10.4274/tjh.2016.0489

Cited by 19 publications

(17 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are in concordance with two studies in Iran and Middle East but different from other studies from other countries including Japan, China, and Europe. 21 , 27–31 For platelet level, the cohort in this study had higher median level than the study by Ni et al but similar with the study by Scholl et al 23 , 26 Based on higher hemoglobin level and lower leukocyte level, the cohort in his study may have better prognosis when compared with other AML studies.…”

Section: Discussionsupporting

confidence: 85%

FLT3-ITD Mutation and FLT3 Ligand Plasma Level Were Not Associated with One-Year Survival of Indonesian Acute Myeloid Leukemia Patients

Rinaldi

Louisa

Sari

et al. 2021

OTT

View full text Add to dashboard Cite

Objective To analyze the association of FLT3-ITD mutation and FLT3 ligand plasma level with one-year survival of Indonesian acute myeloid leukemia (AML) patients. Methods A prospective cohort study was conducted to determine the association between FLT-3-ITD mutation and FLT3 ligand plasma level with one-year survival of Indonesian AML patients. In the study, a total of 51 AML patients were obtained from two tertiary hospitals in Indonesia from year 2018 to 2020. Inclusion criteria were de novo AML male and female patients aged ≥18 years old. Exclusion criteria were prior myelodysplastic syndrome and patients that refused to participate in the study. FLT3-ITD genotype of patients was then analyzed using PCR method while FLT3 ligand plasma level was measured using ELISA method. Patients were then followed-up for 1 year or until death occurred with survival as the measured outcome. Association between independent and dependent variable were analyzed by cox regression proportional hazard. Results Eleven patients (21.5%) in this study had FLT3-ITD mutation. The median age of AML patients was 45 (18–71) years, and the median blast percentage was 50% (5–87%). After one-year follow-up, 33 (64.7%) patients had died. The median survival of AML patients was 6 months. Univariate analysis showed no association between FLT3-ITD mutation status (HR: 1.051 ; 95% CI: 0.483–2.286; P: 0.901) and FLT3 ligand plasma level (HR: 0.798; 95% CI: 0.347–1.837; p= 0.596), and age (HR: 1.283; 95% CI: 0.575–2.862; p= 0.542) with one-year survival of AML patients, but multivariate analysis showed association between GFR with one-year survival of AML patients in this cohort (HR: 4.053; 95% CI: 1.469–11.183; p= 0.007). Conclusion One-year survival of AML patients in Indonesia is not affected by FLT3-ITD mutation and FLT3 ligand plasma level. However, GFR showed association with one-year survival of AML patient in this cohort study.

show abstract

Section: Discussionsupporting

confidence: 85%

FLT3-ITD Mutation and FLT3 Ligand Plasma Level Were Not Associated with One-Year Survival of Indonesian Acute Myeloid Leukemia Patients

Rinaldi

Louisa

Sari

et al. 2021

OTT

View full text Add to dashboard Cite

show abstract

“…Acute myeloid leukemia (AML) is the most familiar hematologic malignancy, characterized by uncontrolled construction of hematopoietic stem cells follow-on in abnormal accumulation of myeloblasts. Generally, based on the cytogenetic abnormalities, the prognosis of AML patients is grouped into three risk groups: good, intermediate, and poor (Rezaei et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Frequency and Prognostic Value of NPM1 Mutations in Sudanese Acute Myeloid Leukemia Patients

Elzain

Khalil

2020

Preprint

View full text Add to dashboard Cite

IntroductionAcute myeloid leukemia (AML) is a malignancy of proliferative, clonal, abnormally, or poorly differentiated cells of the hematopoietic system, characterized by clonal evolution and genetic heterogeneity (Döhner et al, 2015). The molecular genetics of AML regarding the prognosis of patients mainly representing by NPM1. NPM1 is a nucleolar protein that located on chromosome 5q35.1 which shuttles between the nucleus and cytoplasm. It is concerned in multiple functions, including ribosomal protein assembly and transport, control of centrosome duplication, and regulation of the tumor suppressor ARF & p53. NPM1 mutations that relocalize NPM1 from the nucleus into the cytoplasm are associated with development of acute myeloid leukemia (Garzon et al, 2008). The aim of this study was to determine the frequency and clarify the prognostic value of NPM1 mutations among Sudanese patients with acute myeloid leukemia.Materials and MethodsA cross sectional study recruited 100 patients in this study clinically diagnosed firstly (not transformed from any other malignancy) as AML patients based on the diagnostic protocol concern RICK hospital; such as morphological identification, immunophenotyping analysis, and molecular genetics, Of the 100 AML patients, 54% were newly diagnosed and 46% were admitted by chemotherapy treatment and follow up. EDTA blood or bone marrow samples were collected from patients for performing CBC, hematological studies including FAB classification, PCR protocols and sequencing. genomic DNA was extracted from all samples using guanidine method (Ding et al, 2008).ResultsNPM1 mutations detection, sequencing technique was done, and then sequencing analysis by software (Mega 7 Software) (Kumar et al, 2016) revealed that there were no NPM1mutations in Sudanese AML patients.ConclusionThe Sudanese AML patients carry wild type NPM1.

show abstract

“…Rezaei et al showed that there were no significant differences in mean white blood cell counts between cytogenetically normal AML patients with wild-type and mutant FLT3–ITD and NPM1 genes. [ 10 ] But, we did not determine cytogenetics as an exclusion or inclusion criteria in our study. Furthermore, our study was a retrospective study.…”

Section: Discussionmentioning

confidence: 99%

Analysis of pre-chemotherapy WBC, PLT, monocyte, hemoglobin, and MPV levels in acute myeloid leukemia patients with WT1, FLT3, or NPM gene mutations

et al. 2020

View full text Add to dashboard Cite

Effects of mutations on AML (acute myeloid leukemia) patients have been an area of clinical interest. The aim of this study was to analyze pre-chemotherapy WBC (white blood cell), platelet, monocyte, hemoglobin, and mean platelet volume (MPV) levels in acute myeloid leukemia patients with Wilms tumor 1 (WT1), FMS-like tyrosine kinase 3 (FLT3), or nucleophosmin (NPM) gene mutations, attempting to detect and compare possible differences in these values. The study included 71 patients with acute myeloid leukemia known to have WT1, FLT3, or NPM gene mutations. The patients were divided into 3 groups: FLT3-mutated AML patients without any accompanying known mutations other than WT1 at the time of diagnosis (Group 1), NPM-mutated AML patients without any accompanying known mutations other than WT1 at the time of diagnosis (Group 2), WT1-mutated AML patients with no other accompanying known mutations at the time of diagnosis (Group 3). We carried out intergroup comparisons of WBC, platelet (PLT), monocyte, hemoglobin, and MPV levels before chemotherapy. There was a statistically significant difference between the groups in terms of WBC parameters ( P = .001). There were no statistically significant differences between the groups with respect to hemoglobin, platelet, and monocyte levels. Higher white blood cell counts could be observed in patients with FLT3-mutated AML.

show abstract

FMS-like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia (AML) Patients with Normal Karyotype; Mutation Status and Clinical and Laboratory Characteristics

Cited by 19 publications

References 35 publications

FLT3-ITD Mutation and FLT3 Ligand Plasma Level Were Not Associated with One-Year Survival of Indonesian Acute Myeloid Leukemia Patients

FLT3-ITD Mutation and FLT3 Ligand Plasma Level Were Not Associated with One-Year Survival of Indonesian Acute Myeloid Leukemia Patients

Frequency and Prognostic Value of NPM1 Mutations in Sudanese Acute Myeloid Leukemia Patients

Analysis of pre-chemotherapy WBC, PLT, monocyte, hemoglobin, and MPV levels in acute myeloid leukemia patients with WT1, FLT3, or NPM gene mutations

Contact Info

Product

Resources

About